Results 161 to 170 of about 2,368 (193)

Safety and Pharmacokinetics of Nirsevimab in Immunocompromised Children

Pediatrics
BACKGROUND AND OBJECTIVES Immunocompromised children may have increased risk for severe respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI), potentially leading to prolonged hospitalization, intensive care, and death.
Joseph, Domachowske, Ulrika Wählby, Hamrén, Irfana, Banu, Roberta, Baronio, Bhanu, Basavaraju, Anthonet, Koen, Amanda, Leach, Vaishali S, Mankad, Pia S, Pannaraj, Pere, Soler-Palacin, Therese, Takas, Masaaki, Mori, Tonya, Villafana   +12 more
openaire   +2 more sources

Nirsevimab-alip

Clinical Therapeutics, 2023
openaire   +4 more sources

Practical Application of Nirsevimab Recommendations for Infants and Toddlers

Journal of Pediatric Health Care
Respiratory syncytial virus (RSV) is a common respiratory tract infection that causes bronchiolitis and pneumonia in infants and children. It is the leading cause of hospitalization of infants in the United States. Nirsevimab is a long-acting monoclonal antibody recommended for the prevention of severe disease in all infants under 8 months of age and ...
Carol Risko Radcliffe, Gabriella Akkawi, Rebecca A. Carson   +2 more
openaire   +2 more sources

RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing

Pediatrics
BACKGROUND Data describing respiratory syncytial virus (RSV) neutralizing antibody (nAb) levels for nirsevimab, a recently approved, extended half-life, anti-RSV fusion protein (F protein) monoclonal antibody, relative to the previous standard of care, palivizumab ...
Deidre, Wilkins, Ulrika, Wählby Hamrén, Yue, Chang, Lindsay E, Clegg, Joseph, Domachowske, Janet A, Englund, William J, Muller, Amanda, Leach, Elizabeth J, Kelly, Tonya, Villafana   +9 more
openaire   +2 more sources

Nirsevimab Effectiveness at Preventing RSV-Related Hospitalization in Infants

NEJM Evidence
In pivotal trials, nirsevimab showed promising efficacy in reducing hospitalizations for respiratory syncytial virus-associated lower respiratory tract infections (RSV-LRTIs). Nirsevimab's real-world effectiveness needs to be assessed.This population-based study used the French National Health Data System.
Marie Joelle, Jabagi, Jérémie, Cohen, Marion, Bertrand, Martin, Chalumeau, Mahmoud, Zureik   +4 more
openaire   +2 more sources

Safety of timely immunization with nirsevimab in hospitalized preterm infants

Vaccine
We aimed to assess the safety profile of nirsevimab in hospitalized preterm infants (PT). We conducted an observational, uncontrolled, prospective study in clinically stable PT admitted to the neonatal unit. One hundred and ten PT were eligible for immunization; uptake was 93.5 % (n = 103) (median GA and BW of 33 weeks and 1892 g, respectively), and a ...
Giannina, Izquierdo, Rodolfo, Villena, Camila, Cabrera, Javiera, Albornoz, Natalie, Hueichao, Carolina, Guerra, Juan Pablo, Torres   +6 more
openaire   +2 more sources

New drug: nirsevimab

Ge-Bu, 2023
openaire   +1 more source

Nieuw geneesmiddel: nirsevimab

Ge-Bu, 2023
openaire   +1 more source

Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants

New England Journal of Medicine, 2022
William J Muller, Michael E Abram, Amanda Leach   +2 more
exaly  

Nirsevimab: The Hidden Costs

Hospital Pediatrics
Samantha, Neumann, Brian, Alverson
openaire   +2 more sources